Biotechnology

Natera

Natera Director Boxer Sells 11,000 Shares for Approximately $2.39 Million

Natera Partners with CytoDyn to Support Leronlimab Project for Metastatic Colorectal Cancer

Natera Initiates SIGNAL-ER 101 Study and Enrolls First Patients in Breast Cancer Trial

Natera Launches Enhanced Panorama NIPT Test Validated by 3,323-Patient Study

Quinn Emanuel Fined $3M and Mandated Training for Misleading Court in Natera Case

Natera Co-founder Sheena Jonathan Sells Shares in Two Transactions in May

Signatera™ CDx Receives FDA Approval as Companion Diagnostic for Muscle-Invasive Bladder Cancer

QRG Capital Management Inc. Significantly Increased Holdings in Natera Inc.

Natera released FY2026 Q1 earnings on May 7 After-Market (EST), actual revenue USD 696.64 M (forecast USD 617.07 M), actual EPS USD -0.6013 (forecast USD -0.5536)

Natera to Report Fourth Quarter Earnings

Natera co-founder sells company stock

Natera to Release FY2026 Q1 Earnings on May 7 After-Market (EST), Forecast Revenue USD 617.07M, EPS USD -0.5536

Natera Displays New Clinical Evidence for Prospera at ISHLT Conference

Natera Co-founder and Director Sells 1,500 Shares

NTRA Uses SignateraTM MRD Detection to Identify Breast Cancer Patients Without Surgery

Natera Publishes Research Results of Signatera ctDNA Test in Anal and Rectal Cancer

Neuberger Berman Group LLC Increases Stake in Natera Inc.

FactSet: Analysts Lower NTRA-US EPS Estimate for 2026

Natera Inc. to Present New Data on Signatera at ASCO GU

Freecast

Cuprina

U-BX Tech

HORIZON SPACE ACQUISITION II CORP COM USD0.0001 30/03/2026(SUB/RIGHTS)

Defiance Pure Space Dly 2X Strat ETF

VS MEDIA

Everbright Digital

Park Ha Biological Tech

Friedman Industries

Defiance Daily Target 2X Short ASTS ETF

NTRA

Marcus Gail Boxer, a Director, reported sales of Natera common stock on 2026-06-05. The report shows weighted average sale prices of $216.0631, $217.3036 and $218.1084 for three bulk lots and a fourth sale at $218.815. The total proceeds from the transactions were $2,389,328. Following the reported sales, Boxer directly owns 6,183 shares of common stock.Reporter NameMarcus Gail BoxerRelationshipDirectorTypeSellAmount$2,389,328SEC FilingForm 4DisclaimerThis is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

TradingView

Natera Director Sold Shares Worth Over $2.3M

CIEN

INSM

JGRO

The JPMorgan Active Growth ETF (JGRO) experienced a significant week-over-week outflow of approximately $175.2 million, representing a 1.7% decrease in shares outstanding. This reduction from 102.9 million to 101.15 million units reflects investor selling pressure. Concurrently, key underlying holdings such as Ciena Corp, Natera Inc, and Insmed Inc saw declines in their stock prices. The article highlights how large ETF outflows can impact individual component stocks through the destruction of ETF units.

nasdaq

Ciena

Insmed

JPMorgan Active Growth ETF

Nasdaq

JPMorgan Active Growth ETF Experiences Big Outflow

FIVE

Eli Lilly and Natera are among the companies that can keep growing after the artificial-intelligence hype fades. Plus, Five Below’s “squishy dumpling” score.

Five Below

Eli Lilly

Healthcare stocks can benefit from AI, too. But that isn’t the reason to buy them

A $100 investment in Natera (NTRA) ten years ago would be worth approximately $1,733.74 today, reflecting an annualized return of 32.79% and outperforming the market by 19.16%. With a current market cap of $30.47 billion and a share price of $212.73, the article highlights the significant impact of compounded returns on long-term cash growth.

benzinga_article

$100 Invested In Natera 10 Years Ago Would Be Worth This Much Today

SNDK

HUBS

The US market shows robust performance with earnings forecasted to grow 17% annually. Simply Wall St highlights high-growth tech stocks for May 2026, including AppLovin, Sandisk, and Krystal Biotech. Specific focus is given to Natera, Zscaler, and HubSpot, detailing their revenue growth, strategic innovations in diagnostics and cloud security, and recent financial recoveries or guidance upgrades.

Simplywall

Sandisk

HubSpot

Zscaler

Krystal Biotech

AppLovin

iShares US Healthcare Providers

SPDR S&P Software

Invesco Semiconductors ETF

Invesco Biotechnology & Genome ETF

SPDR S&P Biotech

ALPS Medical Breakthrough

iShares Genomics Immunology and Healthcare ETF

iShares Semiconductor ETF

VanEck Semiconductor ETF

iShares US Pharma

Direxion S&P Biotech Bull 3X

Invesco Nasdaq Biotechnology ETF

Proshares Ultra Nasdaq Biotech

Direxion Semicon Bull 3X

ISHRS S&P Glb It

Ark Genomic Revolution ETF

SPDR S&P Semicon

VanEck Biotech ETF

iShares Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

iShares Expanded Tech Software Sector ETF

VG Health

iShares Global Healthcare

Invesco PHLX Semiconductor ETF

Health Care Select Sector SPDR

First Trust Nasdaq Food & Semicon

Global X Cloud Computing ETF

Tradr 2X Long APP Daily ETF

iShares US Medical Devices

Reddit

Palantir Tech

Fabrinet

Marker Therapeutics

Tenaya Therapeutics

Gorilla Tech

Sandisk - WI

GORILLA TECHNOLOGY GROUP INC C/WTS (TO PUR COM)

High Growth Tech Stocks in US for May 2026

John Fesko, an insider at Natera, Inc. (NASDAQ:NTRA), sold 1,438 shares at an average price of $202.84, totaling $291,683.92. Post-transaction, he owns 185,782 shares valued at approximately $37.68 million, marking a 0.77% decrease in ownership. The sale was executed under a Rule 10b5-1 trading plan to cover tax obligations. Natera's stock recently traded at $213.94, with a market cap of $30.64 billion.

Market Beat

Myriad Genetic

Morgan Stanley

JPMorgan Chase

Wells Fargo

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

John Fesko Sells 1,438 Shares of Natera (NASDAQ:NTRA) Stock